Non-erosive Reflux Disease/Diarrheal Irritable Bowel Syndrome
Conditions
Brief summary
To clarify the changes of intestinal flora - gut - brain axis in FGIDs patients represented by NERD disharmony of liver and stomach and IBS-D disharmony of liver and spleen, and confirm that the imbalance between intestinal flora and host co-metabolism is the key to the pathogenesis of functional gastrointestinal disease. To reveal the common mechanism of regulating liver and spleen (stomach) in treating FGIDs dynamic disorder and visceral hypersensitivity by regulating intestinal flora - intestine - brain axis disorder.
Interventions
DRUGtong-jiang granules
This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
DRUGChang 'an II Recipe
This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
DRUGThe placebo of tong-jiang granules
This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
DRUGThe placebo of Chang 'an II Recipe
This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy volunteers with no abnormal clinical manifestations; 2. Meet the diagnostic criteria of NERD syndrome of disharmony of liver and stomach and IBS-D syndrome of liver depression and spleen deficiency. 3. Aged between 18 and 70. 4. Did not take antibiotics, steroids or other hormones, Chinese herbal preparations (including oral and intravenous administration), microecological preparations or probiotics such as yogurt for nearly a week; 5. Subjects are informed and sign informed consent voluntarily; 6. Have certain reading ability.
Exclusion criteria
1. Patients with severe lesions of the heart, liver, kidney and other major organs, hematopoietic system, nervous system or mental diseases; 2. Complicated with other organic diseases of the digestive system (such as peptic ulcer), or systemic diseases that affect the dynamics of the digestive tract (such as hyperthyroidism and diabetes); 3. Ongoing or ongoing use of drugs that may affect gastrointestinal function (antidiarrals, antidepressants, anti-anxiety drugs, intestinal microflora regulation drugs, antibiotics, etc.); 4. Those with a history of allergy to related drugs or severe food allergy used in the research. 5. The body is colonized with metal medical devices. (6) Having a pregnancy plan within three months. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in 7 point Likert scale scores | Baseline, 2 weeks and 4 weeks during treatment period,4 weeks , 8 weeks , 12 weeks and 16 weeks during follow-up period | The score of patients on the degree of remission of gastroesophageal reflux disease symptoms (acid reflux and heartburn) (1 point for obvious improvement of symptoms, 2 points for improvement of symptoms, 3 points for slight improvement of symptoms, 4 points for no change, 5 points for slight aggravation of symptoms, 6 points for aggravation of symptoms, and 7 points for obvious aggravation of symptoms) |
| Changes in irritable bowel syndrome symptom severity scale scores | Baseline, 2 weeks and 4 weeks during treatment period,4 weeks , 8 weeks , 12 weeks and 16 weeks during follow-up period | Irritable bowel syndrome symptom severity scale scores were assessed before and after treatment and during follow-up. The scoring standard is the same as the international standard. |
Countries
China
Contacts
Primary Contactlin lv
Outcome results
None listed